YSI

Know Labs, Inc. Expands IP Leadership in Non-Invasive Diagnostics with New High Performance Glucose Sensor Patent

Retrieved on: 
Wednesday, January 4, 2023
Biotechnology, Technology, Other Health, Diabetes, Health, General Health, Pharmaceutical, Health Technology, Medical Devices, Hospitals, Hardware, Algorithm, IP, Abbott Laboratories, Patent, United States patent law, United States Patent and Trademark Office, Internal, NYSE, Investment, FDA, CGMS-A, MARD, Laboratory, YSI, Medical imaging, Medical device, Dexcom

The new patent extends the Know Labs IP portfolio to nearly 90 patents issued and pending, reinforcing the company’s position as the top worldwide IP holder in non-invasive blood glucose monitoring.

Key Points: 
  • The new patent extends the Know Labs IP portfolio to nearly 90 patents issued and pending, reinforcing the company’s position as the top worldwide IP holder in non-invasive blood glucose monitoring.
  • 11,529,077, titled “High Performance Glucose Sensor,” was just issued by the United States Patent and Trademark Office.
  • This patent explicitly designates a MARD range of 5.0% to 9.9% for Know Lab’s non-invasive diagnostics technology platform.
  • “The high accuracy of the [Know Labs] non-invasive glucose sensor described herein, when compared to lower accuracy glucose sensors such as minimally invasive CGMs and fingerstick glucose sensors, means that the [Know Labs’] non-invasive glucose sensor can be used as a standard or reference sensor against which the accuracy of other glucose sensors are gauged.

Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor

Retrieved on: 
Sunday, June 5, 2022
People, BGM, Life, YSI, Continuous glucose monitor, Facebook, Prenatal nutrition, Prediabetes, ADA, LinkedIn, Ageing, CGM, Category:Scientific & Academic Publishing academic journals, American Diabetes Association, FreeStyle, Statistics, Diabetes, Hypoglycemia, Patient, Comparison, Review, Reliability, T2D, NYSE, Twitter, Population, Association, Accuracy and precision, MARD, Poster, Safety, Medical device, Pharmaceutical industry

"Abbott revolutionized glucose monitoring with our world-leading FreeStyle Libre technology -- the first sensor to eliminate painful fingersticks by offering factory-calibrated continuous glucose monitoring that is affordable, accessible and accurate," said Mahmood Kazemi, M.D., divisional vice president, global medical affairs and chief medical officer of Abbott's diabetes care business. "A sub-8% overall MARD for the FreeStyle Libre 3 system is a significant milestone, not just in terms of CGM innovation, but because it empowers people with diabetes to be more confident when making important diabetes management decisions."

Key Points: 
  • The multi-centerstudy evaluated the accuracy of the FreeStyle Libre 3 system in people with type 1 or type 2 diabetes, aged 4 or older, who were on insulin therapy.
  • FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.
  • Failure to use FreeStyle Libre 3 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.
  • 1Alva S, Brazg R, Castorino K, Liljenquist D, Liu H, and Kipnes M. Performance of the FreeStyle Libre 3 System.